CMMB - Spark Newswire

1 minute read

Chemomab Therapeutics Q3 EPS $(0.04) Beats $(0.33) Estimate

Today, 5:12 AM

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 89.39 percent. This is a 86.54 percent increase over losses of $(0.26) per share

CMMB

3 minute read

Chemomab Presents Clinical Data From Investigator-Initiated Study Showing CM-101 Reduced Inflammatory And Fibrogenesis-Related Biomarkers In Patients With Severe Lung Injury Derived From Covid-19

By Benzinga Newsdesk

Today, 5:12 AM

─New Findings Demonstrate CM-101's Anti-Inflammatory and Anti-Fibrotic Effects Are Highly Relevant to Inflammatory Lung Diseases─ TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd.

CMMB

47 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 5:12 AM

On Tuesday, 838 companies hit new 52-week lows.

$APE

28 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 5:12 AM

During Monday's trading, 528 companies set new 52-week lows.

$APE

46 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 5:12 AM

Monday saw 825 companies set new 52-week lows.

$APE

1 minute read

Earnings

Chemomab Therapeutics: Q2 Earnings Insights

By Benzinga Insights

Today, 5:12 AM

Chemomab Therapeutics (NASDAQ:CMMB) reported its Q2 earnings results on Friday, August 12, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

CMMB

1 minute read

Chemomab Therapeutics Q2 EPS $(0.03) Beats $(0.25) Estimate

By Bill Haddad

Today, 5:12 AM

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.25) by 88 percent. This is a 88.46 percent increase over losses of $(0.26) per share

CMMB

2 minute read

Earnings

Earnings Scheduled For August 12, 2022

By Benzinga Insights

Today, 5:12 AM

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million.

AIM

5 minute read

79 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:12 AM

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.

ADTH

2 minute read

Chemomab Therapeutics Announces Data Supporting Role Of Chemomab’s Novel Therapeutic Target CCL24 In Systemic Sclerosis Presented At EULAR 2022

By Benzinga Newsdesk

Today, 5:12 AM

Chemomab Therapeutics, Ltd. (NASDAQ:CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet

CMMB

Feed Symbols: CMMB